We observed that NRAS and DNMT3A mutations were associated with high relapse rates (41.7% vs. 100%, P=.037 for NRAS; 38.9%, vs. 80.0%, P=.034, for DNMT3A) in adult de novo AML (Supplementary Table S4). The gene discussed is NRAS; the disease is acute myeloid leukemia.